MedTrace Logo

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

NCT06332170 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 610

Last updated 2024-07-18

No results posted yet for this study

Summary

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in combination with other anti-cancer agents in patients with advanced solid tumor patients.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

HS-20093

administered as an IV infusion

DRUG

Adebrelimab

administered as an IV infusion

DRUG

Cisplatin/ Carboplatin

administered as an IV infusion

DRUG

Cetuximab

administered as an IV infusion

DRUG

Enzalutamide

160mg once daily (QD) orally

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-26
Primary Completion
2026-05-30
Completion
2028-05-30
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06332170 on ClinicalTrials.gov